قالب وردپرس درنا توس
Home / Business / Pfizer / BioNTech, Moderna Expect Shot Shot Data Against New COVID-19 Variant

Pfizer / BioNTech, Moderna Expect Shot Shot Data Against New COVID-19 Variant



Blank vials of the “Commirati” Pfizer-BioNTech COVID-19 vaccine were seen in a waste package at a coronavirus vaccine (COVID-19) vaccine center in Madrid, Spain, 24 November 2021. REUTERS / Sergio Perez / File photo

Register now for free unlimited access to reuters.com

  • Look for signs that warrant a vaccine redesign
  • BioNTech says it understands the concerns of experts
  • BioNTech, Pfizer in an effort to establish relaunch routine
  • Moderna also studied booster options for new variant

FRANKFURT, NOVEMBER 26 (Reuters) – BioNTech SE (22UAy.DE) said on Friday that it expects more data on a varying new coronavirus variant detected in South Africa in two weeks to help determine if its vaccine was produced by partner Pfizer Inc. (PFE). .N)) would have to be reworked.

Pfizer and BioNTech have said that if necessary, they expect to send a new vaccine tailored to the emerging variant in approximately 100 days.

“We understand the concern of experts and have immediately initiated investigations on variant B.1.1.529,” BioNTech said in a statement when asked to comment.

Register now for free unlimited access to reuters.com

“We expect more data from the laboratory tests in the last two weeks. The data will provide more information on whether B.1.1.529 may be an escape variant that may require an adjustment of our vaccine if the variant spreads globally.”

Moderna Inc. (MRNA.O) said in a statement that it was working to promote a booster candidate adapted to the new variant and had also tested a higher dose of its existing booster and to study other booster candidates designed to protect against multiple variants. .

“A booster dose of an authorized vaccine represents the only currently available strategy for boost wanting immunity,” Moderna said in the statement.

Escape variants are those that avoid the targeted immune response caused by vaccination. Pfizer and BioNTech would be able to redesign their shot in six weeks and send initial batches in 100 days, BioNTech added.

BioNTech ADRs gained 14.2% to close at $ 348 on Friday and Pfizer shares rose 6.1% to close at $ 54. Moderna gained 20.6% to close at $ 329.63.

Global authorities reacted with alarm on Friday to the new variant, with the i. Read more

Pfizer and BioNTech have already created versions of their established MRNA-based vaccine – based on the original virus found in the Chinese city of Wuhan – to target the so-called alpha and delta variants, with ongoing clinical trials.

These efforts are not meant to yield commercial products; The exercise is done to establish a routine with regulators that will help accelerate any future vaccination.

Analysts at Evercore ISI have said that data from Qatar on another recent variant showed a high level of initial efficacy through current vaccines that faded significantly four months after dosing.

Johnson and Johnson (JNJ.N) have said it is also closely monitoring emerging strains of COVID-19 and is testing the effectiveness of its shot against the new variant.

Register now for free unlimited access to reuters.com

Report by Ludwig Burger in Frankfurt After Reporting by Carl O’Donnell in New York Editing by Kirsten Donovan and Matthew Lewis

Our Standards: The Thomson Reuters Trust Principles.


Source link